The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification

Journal of Thoracic Oncology

Volumn 10, Issue 9, 2015, Pages 1243-1260

  Travis, William D ^a   Brambilla, Elisabeth ^b   Nicholson, Andrew G ^c   Yatabe, Yasushi ^d   Austin, John H M ^e   Beasley, Mary Beth ^f   Chirieac, Lucian R ^g   Dacic, Sanja ^h   Duhig, Edwina ⁱ   Flieder, Douglas B ^j   Geisinger, Kim ^k   Hirsch, Fred R ^l   Ishikawa, Yuichi ^m   Kerr, Keith M ⁿ   Noguchi, Masayuki ^o   Pelosi, Giuseppe ^p   Powell, Charles A ^f   Tsao, Ming Sound ^q   Wistuba, Ignacio ^r  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HÔPITAL MICHALLON   (France)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e NewYork Presbyterian Hospital   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^j FOX CHASE CANCER CENTER   (United States)

^k UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^m CANCER INSTITUTE   (Japan)

ⁿ ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^o UNIVERSITY OF TSUKUBA   (Japan)

^p NATIONAL CANCER INSTITUTE   (Italy)

^q PRINCESS MARGARET HOSPITAL   (Canada)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Carcinoid; Large cell carcinoma; Lung adenocarcinoma; Lung cancer; Lung tumors; Small cell carcinoma; Squamous cell carcinoma; WHO classification

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EWSR1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CLEAR CELL CARCINOMA; CYTOLOGY; EPITHELIOID HEMANGIOENDOTHELIOMA; ERDHEIM CHESTER DISEASE; GENE REARRANGEMENT; GERM CELL TUMOR; HAMARTOMA; HEMANGIOENDOTHELIOMA; HISTIOCYTOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAPULMONARY THYMOMA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SARCOMA; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MENINGIOMA; MYOEPITHELIOMA; NEUROENDOCRINE TUMOR; NUT CARCINOMA; PECOMATOUS TUMOR; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PULMONARY HAMARTOMA; PULMONARY MYXOID SARCOMA; REVIEW; SARCOMATOID CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION; CLASSIFICATION; FEMALE; GENETICS; HISTORY; MALE; ORGANIZATION AND MANAGEMENT; PATHOLOGY;

FEMALE; HISTORY, 21ST CENTURY; HUMANS; LUNG NEOPLASMS; MALE; WORLD HEALTH ORGANIZATION;

EID: 84940100919     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000630     Document Type: Review

References (164)

1. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 2015 Lyon International Agency for Research on Cancer
2. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology 2000 3rd ed. Geneva World Health Organization (WHO)
3. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart 2004 Lyon IARC
4. World Health Organization Histological typing of lung tumours 1967 Geneva World Health Organization
5. World Health Organization Histological typing of lung tumors 1981 Geneva World Health Organization
6. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, in collaboration with LHS, Countries pf Histological typing of lung and pleural tumors 1999 Berlin Springer
7. Travis WD, Brambilla E, Noguchi M, The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol 2011 6 244 285
8. Nivolumab approved for lung cancer. Cancer Discov 2015 5 OF1
9. Lindeman NI, Cagle PT, Beasley MB, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013 8 823 859
10. Leighl NB, Rekhtman N, Biermann WA, Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014 32 3673 3679
11. Travis WD, Brambilla E, Noguchi M, Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013 137 668 684
12. Ou SH, Zell JA, Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009 4 1202 1211
13. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM, Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010 5 442 447
14. Nicholson AG, Gonzalez D, Shah P, Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010 5 436 441
15. Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM, Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000 53 537 540
16. Travis WD, Rekhtman N, Riley GJ, Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010 5 411 414
17. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J, Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012 136 163 171
18. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N, p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012 25 405 415
19. Pelosi G, Fabbri A, Bianchi F, ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012 7 281 290
20. Nonaka D, A study of ΔNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 2012 36 895 899
21. Rekhtman N, Tafe LJ, Chaft JE, Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 2013 26 511 522
22. Travis WD, Brambilla E, Riely GJ, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013 31 992 1001
23. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012 489 519 525
24. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014 511 543 50
25. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM) A genomics-based classification of human lung tumors. Sci Transl Med 2013 5 209ra153
26. Barletta JA, Yeap BY, Chirieac LR, Prognostic significance of grading in lung adenocarcinoma. Cancer 2010 116 659 669
27. Kadota K, Suzuki K, Kachala SS, A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 2012 25 1117 1127
28. Nakazato Y, Maeshima AM, Ishikawa Y, Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma. J Thorac Oncol 2013 8 736 743
29. Nakazato Y, Minami Y, Kobayashi H, Nuclear grading of primary pulmonary adenocarcinomas: correlation between nuclear size and prognosis. Cancer 2010 116 2011 2019
30. Sica G, Yoshizawa A, Sima CS, A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010 34 1155 1162
31. Yoshizawa A, Motoi N, Riely GJ, Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011 24 653 664
32. Warth A, Muley T, Meister M, The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012 30 1438 1446
33. Duhig EE, Dettrick A, Godbolt DB, Mitosis trumps T stage and proposed international association for the study of lung cancer/American thoracic society/European respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma. J Thorac Oncol 2015 10 673 681
34. von der Thüsen JH, Tham YS, Pattenden H, Prognostic significance of predominant histologic pattern and nuclear grade in resected adenocarcinoma of the lung: potential parameters for a grading system. J Thorac Oncol 2013 8 37 44
35. Kadota K, Nitadori J, Woo KM, Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 2014 9 1126 1139
36. Sigel CS, Rudomina DE, Sima CS, Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathol 2012 120 35 43
37. Kadota K, Yeh YC, Villena-Vargas J, Tumor budding correlates with protumor immune microenvironment and is an independent prognostic factor for recurrence of stage I lung adenocarcinoma. Chest 2015. [Epub ahead of print].
38. Yamaguchi Y, Ishii G, Kojima M, Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol 2010 5 1361 1368
39. Taira T, Ishii G, Nagai K, Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. Lung Cancer 2012 76 423 430
40. Travis WD, Brambilla E, Noguchi M, Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013 137 685 705
41. Kadota K, Nitadori J, Rekhtman N, Jones DR, Adusumilli PS, Travis WD, Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol 2015. [Epub ahead of print].
42. Rekhtman N, Paik PK, Arcila ME, Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012 18 1167 1176
43. Kadota K, Villena-Vargas J, Yoshizawa A, Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 2014 38 448 460
44. Lim HJ, Ahn S, Lee KS, Persistent pure ground-glass opacity lung nodules ≥ 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications. Chest 2013 144 1291 1299
45. Lee HY, Choi YL, Lee KS, Pure ground-glass opacity neoplastic lung nodules: histopathology, imaging, and management. AJR Am J Roentgenol 2014 202 W224 W233
46. Isaka T, Yokose T, Ito H, Comparison between CT tumor size and pathological tumor size in frozen section examinations of lung adenocarcinoma. Lung Cancer 2014 85 40 46
47. Naidich DP, Bankier AA, MacMahon H, Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013 266 304 317
48. Girard N, Deshpande C, Lau C, Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009 33 1752 1764
49. Kadota K, Yeh YC, Sima CS, The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol 2014 27 690 700
50. Mackinnon AC Jr, Luevano A, de Araujo LC, Rao N, Le M, Suster S, Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma. Mod Pathol 2014 27 1063 1072
51. Warth A, Muley T, Kossakowski C, Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma. J Thorac Oncol 2015 10 638 644
52. Thunnissen E, Beasley MB, Borczuk AC, Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012 25 1574 1583
53. Warth A, Cortis J, Fink L, Pulmonary Pathology Working Group of the German Society of Pathology Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch 2012 461 185 193
54. Nitadori J, Bograd AJ, Kadota K, Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst 2013 105 1212 1220
55. Onozato ML, Kovach AE, Yeap BY, Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol 2013 37 287 294
56. Kadota K, Nitadori J, Sima CS, Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. J Thorac Oncol 2015 10 806 814
57. Warth A, Muley T, Kossakowski CA, Prognostic impact of intra-alveolar tumor spread in pulmonary adenocarcinoma. Am J Surg Pathol 2015 39 793 801
58. Loukeri AA, Kampolis CF, Ntokou A, Tsoukalas G, Syrigos K, Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis. Clin Lung Cancer 2015 16 15 23
59. Klempner SJ, Ignatius Ou SH, Costa DB, The clinical use of genomic profiling to distinguish intrapulmonary metastases from synchronous primaries in non-small-cell lung cancer: a mini-review. Clin Lung Cancer 2015. [Epub ahead of print].
60. Murphy SJ, Aubry MC, Harris FR, Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer. J Clin Oncol 2014 32 4050 4058
61. Girard N, Deshpande C, Azzoli CG, Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest 2010 137 46 52
62. Girard N, Ostrovnaya I, Lau C, Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009 15 5184 5190
63. Xue X, Liu Y, Pan L, Diagnosis of multiple primary lung cancer: a systematic review. J Int Med Res 2013 41 1779 1787
64. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y, Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients-based on a hospital study in China. Eur J Surg Oncol 2013 39 1262 1268
65. Takahashi M, Shigematsu Y, Ohta M, Tokumasu H, Matsukura T, Hirai T, Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters. J Thorac Cardiovasc Surg 2014 147 54 59
66. Tsuta K, Kawago M, Inoue E, The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 2013 81 371 376
67. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G, New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 2013 8 612 618
68. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G, The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg 2014 98 453 458
69. Yoshizawa A, Sumiyoshi S, Sonobe M, Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013 8 52 61
70. Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA, Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011 6 1496 1504
71. Woo T, Okudela K, Mitsui H, Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int 2012 62 785 791
72. Cha MJ, Lee HY, Lee KS, Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. J Thorac Cardiovasc Surg 2014 147 921 928.e2
73. Nitadori JI, Bograd AJ, Kadota K, Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer Inst 2013 105 1212 1220
74. Ujiie H, Kadota K, Chaft J, Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival. J Clin Oncol 2015. in press.
75. Tsao MS, Marguet S, Le Teuff G, Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 2015. [Epub ahead of print].
76. Brambilla C, Laffaire J, Lantuejoul S, Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity. Clin Cancer Res 2014 20 5777 5786
77. Barnes L, Eveson JW, Reichart P, Sidransky D, Pathology and genetics of head and neck tumours. 2005 Lyon International Agency for Research on Cancer
78. Brambilla E, Moro D, Veale D, Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol 1992 23 993 1003
79. Moro-Sibilot D, Lantuejoul S, Diab S, Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 2008 31 854 859
80. Kim DJ, Kim KD, Shin DH, Ro JY, Chung KY, Basaloid carcinoma of the lung: a really dismal histologic variant? Ann Thorac Surg 2003 76 1833 1837
81. Wang LC, Wang L, Kwauk S, Analysis on the clinical features of 22 basaloid squamous cell carcinoma of the lung. J Cardiothorac Surg 2011 6 10
82. Herbst RS, Gandara DR, Hirsch FR, Lung master protocol (Lung-MAP)-A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 2015 21 1514 1524
83. Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM, Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. Arch Pathol Lab Med 2014 138 626 635
84. Rossi G, Mengoli MC, Cavazza A, Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch 2014 464 61 68
85. (NGM) CLCGPCNGM A genomics-based classification of human lung tumors. Sci Transl Med 2013 5 209ra153
86. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS, US lung cancer trends by histologic type. Cancer 2014 120 2883 2892
87. Caplin ME, Baudin E, Ferolla P, Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoid. Ann Oncol 2015 26 1604 1620
88. Fernandez-Cuesta L, Peifer M, Lu X, Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 2014 5 3518
89. Pelosi G, Rindi G, Travis WD, Papotti M, Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 2014 9 273 284
90. Pelosi G, Rodriguez J, Viale G, Rosai J, Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005 29 179 187
91. Walts AE, Ines D, Marchevsky AM, Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol 2012 25 1258 1264
92. Travis WD, Rush W, Flieder DB, Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998 22 934 944
93. Yendamuri S, Caty L, Pine M, Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery 2012 152 397 402
94. Italiano A, Cortot AB, Ilie M, EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009 125 2479 2482
95. Pelosi G, Scarpa A, Manzotti M, K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. Mod Pathol 2004 17 538 546
96. Chang YL, Wu CT, Shih JY, Lee YC, EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol 2011 18 2952 2960
97. Kaira K, Horie Y, Ayabe E, Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010 5 460 465
98. Leone A, Graziano P, Gasbarra R, Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer 2011 128 732 735. author reply 736.
99. Lee S, Kim Y, Sun JM, Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011 137 1203 1211
100. Dacic S, Finkelstein SD, Sasatomi E, Swalsky PA, Yousem SA, Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. Am J Surg Pathol 2002 26 510 516
101. Holst VA, Finkelstein S, Colby TV, Myers JL, Yousem SA, p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis. Am J Surg Pathol 1997 21 801 811
102. Pardo J, Aisa G, de Alava E, Primary mixed squamous carcinoma and osteosarcoma (carcinosarcomas) of the lung have a CGH mapping similar to primitive squamous carcinomas and osteosarcomas. Diagn Mol Pathol 2008 17 151 158
103. Pelosi G, Gasparini P, Cavazza A, Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer 2012 77 507 514
104. Toyokawa G, Takenoyama M, Taguchi K, The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene. Lung Cancer 2013 81 491 494
105. Macher-Goeppinger S, Penzel R, Roth W, Expression and mutation analysis of EGFR, c-KIT, and β-catenin in pulmonary blastoma. J Clin Pathol 2011 64 349 353
106. Nakatani Y, Masudo K, Miyagi Y, Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol 2002 15 617 624
107. Sekine S, Shibata T, Matsuno Y, Beta-catenin mutations in pulmonary blastomas: association with morule formation. J Pathol 2003 200 214 221
108. Bodner SM, Koss MN, Mutations in the p53 gene in pulmonary blastomas: immunohistochemical and molecular studies. Hum Pathol 1996 27 1117 1123
109. Bauer DE, Mitchell CM, Strait KM, Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012 18 5773 5779
110. French CA, Kutok JL, Faquin WC, Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol 2004 22 4135 4139
111. French CA, Demystified molecular pathology of NUT midline carcinomas. J Clin Pathol 2010 63 492 496
112. Haack H, Johnson LA, Fry CJ, Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009 33 984 991
113. Schwartz BE, Hofer MD, Lemieux ME, Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 2011 71 2686 2696
114. Devouassoux-Shisheboran M, Hayashi T, Linnoila RI, Koss MN, Travis WD, A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. Am J Surg Pathol 2000 24 906 916
115. Chan AC, Chan JK, Pulmonary sclerosing hemangioma consistently expresses thyroid transcription factor-1 (TTF-1): a new clue to its histogenesis. Am J Surg Pathol 2000 24 1531 1536
116. Niho S, Suzuki K, Yokose T, Kodama T, Nishiwaki Y, Esumi H, Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung. Am J Pathol 1998 152 1065 1069
117. Dal Cin P, Kools P, De Jonge I, Moerman P, Van de Ven W, Van den Berghe H, Rearrangement of 12q14-15 in pulmonary chondroid hamartoma. Genes Chromosomes Cancer 1993 8 131 133
118. Fletcher JA, Longtine J, Wallace K, Mentzer SJ, Sugarbaker DJ, Cytogenetic and histologic findings in 17 pulmonary chondroid hamartomas: evidence for a pathogenetic relationship with lipomas and leiomyomas. Genes Chromosomes Cancer 1995 12 220 223
119. Xiao S, Lux ML, Reeves R, Hudson TJ, Fletcher JA, HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol 1997 150 901 910
120. Tomashefski JF Jr., Benign endobronchial mesenchymal tumors: their relationship to parenchymal pulmonary hamartomas. Am J Surg Pathol 1982 6 531 540
121. Carsillo T, Astrinidis A, Henske EP, Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000 97 6085 6090
122. Martignoni G, Pea M, Reghellin D, Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med 2010 134 33 40
123. D'Armiento J, Imai K, Schiltz J, Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Cancer Res 2007 67 1902 1909
124. McCormack FX, Travis WD, Colby TV, Henske EP, Moss J, Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012 186 1210 1212
125. Flieder DB, Travis WD, Clear cell "sugar" tumor of the lung: association with lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in a patient with tuberous sclerosis. Am J Surg Pathol 1997 21 1242 1247
126. Pileri SA, Cavazza A, Schiavina M, Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change. Histopathology 2004 44 156 163
127. Lawson K, Maher TM, Hansell DM, Nicholson AG, Successful treatment of progressive diffuse PEComatosis. Eur Respir J 2012 40 1578 1580
128. Maruyama H, Seyama K, Sobajima J, Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene. Mod Pathol 2001 14 609 614
129. Gaffey MJ, Mills SE, Ritter JH, Clear cell tumors of the lower respiratory tract. Semin Diagn Pathol 1997 14 222 232
130. Chen YB, Guo LC, Huang JA, Ji C, Ling CH, Clear cell tumor of the lung: a retrospective analysis. Am J Med Sci 2014 347 50 53
131. Gaffey MJ, Mills SE, Zarbo RJ, Weiss LM, Gown AM, Clear cell tumor of the lung. Immunohistochemical and ultrastructural evidence of melanogenesis. Am J Surg Pathol 1991 15 644 653
132. Lantuejoul S, Isaac S, Pinel N, Negoescu A, Guibert B, Brambilla E, Clear cell tumor of the lung: an immunohistochemical and ultrastructural study supporting a pericytic differentiation. Mod Pathol 1997 10 1001 1008
133. Inoki K, Corradetti MN, Guan KL, Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005 37 19 24
134. Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR, Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol 2015 39 132 139
135. Lau K, Massad M, Pollak C, Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 2011 140 1312 1318
136. Mendlick MR, Nelson M, Pickering D, Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol 2001 25 684 687
137. Errani C, Zhang L, Sung YS, A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011 50 644 653
138. Patel NR, Salim AA, Sayeed H, Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. Histopathology 2015. [Epub ahead of print].
139. Tanas MR, Sboner A, Oliveira AM, Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011 3 98ra82
140. Antonescu CR, Le Loarer F, Mosquera JM, Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 2013 52 775 784
141. Bagan P, Hassan M, Le Pimpec Barthes F, Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature. Ann Thorac Surg 2006 82 2010 2013
142. Nicholson AG, Baandrup U, Florio R, Sheppard MN, Fisher C, Malignant myxoid endobronchial tumour: a report of two cases with a unique histological pattern. Histopathology 1999 35 313 318
143. Thway K, Nicholson AG, Lawson K, Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. Am J Surg Pathol 2011 35 1722 1732
144. Thway K, Nicholson AG, Wallace WA, Al-Nafussi A, Pilling J, Fisher C, Endobronchial pulmonary angiomatoid fibrous histiocytoma: two cases with EWSR1-CREB1 and EWSR1-ATF1 fusions. Am J Surg Pathol 2012 36 883 888
145. Thway K, Fisher C, Tumors with EWSR1-CREB1 and EWSR1-ATF1 fusions: the current status. Am J Surg Pathol 2012 36 e1 e11
146. Fletcher CDM, Antonescu C, Heim S, Hornick JL, Fletcher JA, Bridge PCW, Hogendoorn F, Mertens, Myoepithelioma/myoepithelial carcinoma/mixed tumor. WHO Classification of Tumours of Soft Tissue and Bone 2013 4th Ed. Lyon IARC 208 209
147. Hornick JL, Fletcher CD, Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol 2003 27 1183 1196
148. Hysi I, Wattez H, Benhamed L, Porte H, Primary pulmonary myoepithelial carcinoma. Interact Cardiovasc Thorac Surg 2011 13 226 228
149. Kourda J, Ismail O, Smati BH, Ayadi A, Kilani T, El Mezni F, Benign myoepithelioma of the lung-a case report and review of the literature. Cases J 2010 3 25
150. Masuya D, Haba R, Huang CL, Yokomise H, Myoepithelial carcinoma of the lung. Eur J Cardiothorac Surg 2005 28 775 777
151. Sarkaria IS, DeLair D, Travis WD, Flores RM, Primary myoepithelial carcinoma of the lung: a rare entity treated with parenchymal sparing resection. J Cardiothorac Surg 2011 6 27
152. Antonescu CR, Zhang L, Chang NE, EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer 2010 49 1114 1124
153. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L, The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013 72 1691 1695
154. Diamond EL, Dagna L, Hyman DM, Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014 124 483 492
155. Arnaud L, Pierre I, Beigelman-Aubry C, Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010 62 3504 3512
156. Haroche J, Arnaud L, Cohen-Aubart F, Erdheim-Chester disease. Curr Rheumatol Rep 2014 16 412
157. Brun AL, Touitou-Gottenberg D, Haroche J, Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol 2010 20 2579 2587
158. Rush WL, Andriko JA, Galateau-Salle F, Pulmonary pathology of Erdheim-Chester disease [In Process Citation]. ModPathol 2000 13 747 54
159. Haroche J, Charlotte F, Arnaud L, High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012 120 2700 2703
160. Chetritt J, Paradis V, Dargere D, Chester-Erdheim disease: a neoplastic disorder. Hum Pathol 1999 30 1093 1096
161. Vencio EF, Jenkins RB, Schiller JL, Clonal cytogenetic abnormalities in Erdheim-Chester disease. Am J Surg Pathol 2007 31 319 321
162. Gong L, He XL, Li YH, Clonal status and clinicopathological feature of Erdheim-Chester disease. Pathol Res Pract 2009 205 601 607
163. Tzoulis C, Schwarzlmüller T, Gjerde IO, Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes 2015 8 171
164. Haroche J, Cohen-Aubart F, Emile JF, Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol 2015 33 411 418